Tia L. Bush Sells 11,000 Shares of Centessa Pharmaceuticals plc (NASDAQ:CNTA) Stock

Centessa Pharmaceuticals plc (NASDAQ:CNTA) CTO Tia L. Bush sold 11,000 shares of the business’s stock in a transaction on Monday, February 3rd. The shares were sold at an average price of $16.86, for a total transaction of $185,460.00. Following the completion of the transaction, the chief technology officer now directly owns 121,503 shares of the company’s stock, valued at $2,048,540.58. This trade represents a 8.30 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink.

Centessa Pharmaceuticals Stock Performance

Shares of Centessa Pharmaceuticals stock opened at $17.24 on Thursday. The company has a debt-to-equity ratio of 0.15, a current ratio of 21.52 and a quick ratio of 21.52. The firm has a market cap of $2.27 billion, a price-to-earnings ratio of -11.27 and a beta of 1.53. The stock’s 50-day moving average is $16.74 and its 200-day moving average is $15.28. Centessa Pharmaceuticals plc has a one year low of $7.38 and a one year high of $18.97.

Centessa Pharmaceuticals (NASDAQ:CNTA) last released its earnings results on Tuesday, November 12th. The company reported ($0.37) EPS for the quarter, beating the consensus estimate of ($0.42) by $0.05. Equities analysts predict that Centessa Pharmaceuticals plc will post -1.6 earnings per share for the current fiscal year.

Institutional Trading of Centessa Pharmaceuticals

Institutional investors have recently made changes to their positions in the business. Janus Henderson Group PLC bought a new position in Centessa Pharmaceuticals in the third quarter valued at $20,698,000. Franklin Resources Inc. boosted its stake in shares of Centessa Pharmaceuticals by 99.1% during the 3rd quarter. Franklin Resources Inc. now owns 2,302,546 shares of the company’s stock worth $38,360,000 after buying an additional 1,145,823 shares during the last quarter. Point72 Asset Management L.P. grew its holdings in shares of Centessa Pharmaceuticals by 54.1% in the 3rd quarter. Point72 Asset Management L.P. now owns 2,715,663 shares of the company’s stock valued at $43,423,000 after acquiring an additional 953,659 shares in the last quarter. Baker BROS. Advisors LP increased its position in shares of Centessa Pharmaceuticals by 123.4% in the third quarter. Baker BROS. Advisors LP now owns 1,227,178 shares of the company’s stock valued at $19,623,000 after acquiring an additional 677,966 shares during the last quarter. Finally, Ally Bridge Group NY LLC bought a new stake in Centessa Pharmaceuticals during the third quarter worth about $4,951,000. Institutional investors own 82.01% of the company’s stock.

Analyst Upgrades and Downgrades

CNTA has been the subject of a number of research analyst reports. TD Cowen assumed coverage on Centessa Pharmaceuticals in a research note on Tuesday, January 7th. They issued a “buy” rating for the company. Guggenheim boosted their price objective on Centessa Pharmaceuticals from $24.00 to $28.00 and gave the company a “buy” rating in a research report on Friday, November 15th. Seven investment analysts have rated the stock with a buy rating, According to MarketBeat.com, Centessa Pharmaceuticals presently has a consensus rating of “Buy” and a consensus price target of $25.83.

About Centessa Pharmaceuticals

Centessa Pharmaceuticals plc, a clinical-stage pharmaceutical company, discovers, develops, and delivers medicines for patients. Its products pipeline includes SerpinPC, an activated protein C inhibitor for the treatment of hemophilia A and B; and ORX750, an orally administered OX2R agonist for the treatment of narcolepsy and other sleep disorders.